All News

Ayal Aizer, MD, MHS, explains how expanded trial data have broadened eligibility for stereotactic radiosurgery in patients with brain metastases, including higher tumor counts.

In a SEER-based cohort of more than 20,000 adults, 5-year Hodgkin lymphoma survivors had nearly double the all-cause mortality of the general population.

The European Commission based its approval of teclistamab plus daratumumab for relapsed/refractory multiple myeloma on data from the MajesTEC-3 study.

The FDA accepted a priority review application for dostarlimab in untreated dMMR/MSI-H locally advanced rectal cancer, backed by AZUR-1 trial data.

Sunil Singhal, MD, discussed how fluorescence imaging via abenacianine helps surgeons visualize tumors missed during lung cancer surgery.

Frank McCormick, PhD, FRS, DSc (Hon), spoke about how targeting KRAS may eventually lead to the prevention of pancreatic cancer.

Lizza Hendriks, MD, PhD, discussed why excluding patients with brain metastases from clinical trials is no longer ethical.

Sunil Singhal, MD, explained how a fluorescent dye technology helps surgeons see and remove tumors more completely.

The platinum-free interval is prognostic but not predictive for lenvatinib plus pembrolizumab, Susana Campos, MD, MPH, told CancerNetwork.

Experts compared outcomes for NALIRIFOX in patients with metastatic pancreatic cancer based on real-world and clinical trial data.

Five-year follow-up showed 37% overall survival rate with lenvatinib plus pembrolizumab in dMMR endometrial cancer.

Up to 55% of endometrial tumors show HER2/neu heterogeneity, explained Susana Campos, MD, MPH, making biopsy at recurrence key for ADC eligibility.

The next major problem to tackle for SRS in brain metastases management is how to handle necrosis rates, according to Ayal Aizer, MD, MHS.

Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.

Experts discussed proactive strategies for managing diarrhea and making dose reduction decisions with NALIRIFOX in pancreatic cancer.

Patients in US counties with the highest medical debt burden had higher odds of stage IV cancer diagnosis and worse survival than those in the lowest-burden counties.

Two teams of multiple myeloma experts debate the use of early CAR T-cell therapies and bispecific antibodies based on key trial data and various hot topics.

Experts highlight how AI-based tools can assist with digital pathology, documentation, medical imaging, and other relevant areas in genitourinary oncology.

The FDA cited outstanding manufacturing observations while raising no concerns about clinical data, bioequivalence, or stability in its CRL.

A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.

Bispecific antibodies “will form the standard backbone agents for multiple myeloma therapies,” according to Hans Lee, MD.

Experts discussed how NALIRIFOX compares with FOLFIRINOX and gemcitabine/nab-paclitaxel as frontline therapy for metastatic pancreatic cancer.

The FDA granted fast track designation to safusidenib for IDH1-mutant glioma, building on updated phase 2 data and a broadening clinical development program.

Phase 3 LITESPARK-011 results show belzutifan/lenvatinib significantly improved PFS and ORR vs cabozantinib in previously treated advanced ccRCC.

Experts gathered to discuss various facets of early-relapse multiple myeloma treatment, such as exposure vs refractoriness and CAR T vs bispecifics.

Barbara Burtness, MD, outlined the rationale behind OrigAMI-4 eligibility criteria and how tumor boards can select patients with HNSCC for amivantamab.

A nurse practitioner, clinical social worker, and patient discuss navigating treatment-related concerns and psychosocial considerations in multiple myeloma.

[68Ga] Ga-NYM096 is the first China-originated radiopharmaceutical to receive FDA breakthrough therapy designation for ccRCC.

In a phase 2 trial, pembrolizumab/denosumab produced a 31% objective response rate in patients with pretreated advanced clear cell renal cell carcinoma.

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.